Through Calls for Proposals, we find smart new ideas to help to alleviate the burden of diseases such as HIV/AIDS, tuberculosis and malaria, which often affect the poorest people in society.
In the context of maternal and child health, Unitaid has identified the opportunity to support the elimination target of congenital transmission of Chagas disease in endemic countries.
For the purpose of this call, Unitaid defines ‘long-acting products’ to mean sustained/extended release products that allow slow absorption of administered drugs maintaining their effects over long periods of time (i.e., over a week for oral products, over a month for injectables and other devices such as implants, patches or rings). The expected change in public health impact for the new products, compared to current daily oral formulations, would need to be explained in each case as it differs depending on disease and indication.
More than one-third of the world’s population – over 2.5 billion people – is at risk of Plasmodium vivax (P. vivax) malaria – the second most common species of malaria. P. vivax occurs in high burden countries but also accounts for over 70% of malaria cases in countries approaching elimination. It can cause severe disease and death, and represents a major financial burden to patients and their caregivers. High-risk groups include migrant populations, the rural poor, and other marginalized groups, as well as children under 5 who have the greatest chance of suffering negative health consequences as a result of their infection.
Under this Call, Unitaid is soliciting proposals for the following interventions aimed at accelerating the availability, adoption and scale-up of improved tools to identify severe disease.
Unitaid aims to improve cure rates for people affected by MDR TB by addressing concrete challenges where measurable impact may be achieved, using technologies that are available (or soon will be) in a targeted timeframe, and filling concrete gaps in the global response. Through extensive outreach and consultations with TB stakeholders, Unitaid has worked to understand the evolving challenges and identify potential opportunities that could align with its strategy and model – with a focus on those with potential to provide significant improvements to the lives of people affected by MDR TB.
The use of Long Lasting Insecticidal Nets (LLINs) accounts for 69 percent of the malaria cases averted since 2001. But increasing insecticide resistance threatens these gains. Together with the Global Fund and the President's Malaria Initiative, Unitaid is seeking proposals to gather evidence and to implement pilot studies to demonstrate the added value of next-generation insecticidal nets.
This Call is focused on accelerating access to better, faster and more robust DR-TB treatment with corresponding diagnostic needs.